JD HEALTH (06618) surged nearly 4% in early trading, with a 3.19% increase to HK$63 by the time of reporting, recording a turnover of HK$149 million. The rise follows reports of heightened demand for respiratory infection testing amid the ongoing flu season. Data from JD HEALTH shows a significant surge in sales of flu test kits, with multi-test kits emerging as a new trend. To meet demand, JD HEALTH has partnered with brands to implement a supply guarantee mechanism, ensuring stable availability without price hikes. Last month, its medical equipment division formed an IVD brand alliance with multiple companies to forecast demand and optimize inventory. Additionally, JD HEALTH has upgraded delivery efficiency, offering same-hour delivery in select regions.
In another development, JD HEALTH exclusively launched a 15mg×18 sachet course pack of Tamiflu® (oseltamivir) granules, addressing the challenges of dosage mismatch and medication waste in pediatric flu treatment. Designed for a standard 5-day course, this pack caters to children aged 1+ and weighing under 15kg, simplifying medication management for parents. Since its launch, daily sales have grown over 100%, making it a top choice for household flu preparedness.
Comments